CompletedPhase 1NCT02580552
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- miRagen Therapeutics, Inc.
- Principal Investigator
- Diana M. Escolar, MD, FAANmiRagen Therapeutics, Inc.
- Intervention
- Cobomarsen(drug)
- Enrollment
- 66 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2020
Study locations (19)
- City of Hope, Duarte, California, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- UCLA Department of Medicine, Los Angeles, California, United States
- Chao Family Comprehensive Cancer Center at University of California, Irvine, Orange, California, United States
- Stanford University Hospital and Clinics, Stanford, California, United States
- University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States
- Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Northwestern University; Department of Dermatology, Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02580552 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07388563Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center